Dr. Georgios Pongas, MD

Dr. Pongas practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Pongas' NPI, 1487974770, was assigned on June 9, 2010. Dr. Pongas graduated from University of Crete School of Health Sciences in 2007. Dr. Pongas holds Florida license ME142533.

Dr. Pongas' primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Pongas' primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Pongas is also affiliated with Jackson Memorial Hospital. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Pongas practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Pongas' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Pongas is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Pongas' licenses on file in 5 states: Florida, Minnesota, New York, District of Columbia and Maryland.

Dmand AI lists chronic leukemia, lymphoma and multiple myeloma among the conditions Dr. Pongas treats.

CMS data shows 370 Medicare services from Dr. Pongas across 4 procedure codes in 2024, for 132 Medicare patients. Medicare paid $36,191 for them.

CMS counts 132 Medicare patients who saw Dr. Pongas in 2024. The largest group is 65 to 74, with 48 patients. 75% of them have high cholesterol, and 70% have high blood pressure. 45% are also on Medicaid. Their average risk score is 2.42, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Pongas' median patient age at 70, with 44% women.

In 2024, Dr. Pongas wrote 405 Medicare Part D claims for 55 patients. 67% of them were for generic drugs. CMS names the drug for 323 of them, across 12 drugs with 11 or more claims each, at $1,757,101 in total drug cost. In 2023, CMS named 210 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Pongas for performance year 2024, reported as part of a group. Dr. Pongas accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Pongas as offering telehealth.

Dmand AI links 28 papers to Dr. Pongas, published from 2009 to 2025. 2024 was the busiest year, with 5. The most frequent topics are Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols and Brentuximab Vedotin. Dr. Pongas has published most often in Blood Adv. Dr. Pongas' most frequent co-authors are Dimitrios P. Kontoyiannis, MD, Juan Pablo Alderuccio, MD and Izidore Lossos, MD.

Dmand AI links Dr. Pongas to 1 clinical trial. Conditions studied include Leukemia, Lymphocytic, Chronic, B-Cell and Leukemia, B-Cell.

CMS Open Payments shows 42 general payments to Dr. Pongas from 15 drug and device companies from 2020 to 2025. Consulting fees make up the largest share, 83% of the total. ADC Therapeutics America, Inc. paid the most, $10,692.

Dmand AI lists 3 awards for Dr. Pongas, most recently AMC Lab/Translational Scholar Program in 2023.

Dr. Pongas graduated from University of Crete School of Health Sciences in 2007. Dr. Pongas is a member of ACP.

Dr. Pongas is in network with 12 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.